Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome (MATOCSS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00527566|
Recruitment Status : Completed
First Posted : September 11, 2007
Results First Posted : March 22, 2017
Last Update Posted : March 22, 2017
|Condition or disease||Intervention/treatment||Phase|
|Churg Strauss Syndrome||Biological: Mepolizumab||Phase 1 Phase 2|
- Document the safety of mepolizumab therapy in patients with CSS.
- Demonstrate the steroid sparing effect of mepolizumab therapy by decreasing corticosteroid dosage while using this anti-IL5 therapy.
Demonstrate the efficacy of anti-IL5 therapy in improving the signs and symptoms of CSS by:
- Measuring serum markers of CSS disease activity, including: peripheral eosinophilia, erythrocyte sedimentation rate, anti- neutrophil cytoplasmic antigen, C-reactive protein and IgE levels.
- Assessing the activity level of vasculitis via the Birmingham Vasculitis Activity Score
- Evaluating asthmatic response via serial peak flow and FEV1 measurements as well as asthma symptom scores using the Juniper scale.
- Assessing changes in novel parameters such as fractional excretion of nitric oxide and IL-5 levels.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||August 2009|
Subjects will receive open-label mepolizumab
IV mepolizumab, 750 mg
Other Name: Anti IL-5
- Number of Participants With Indicated Side Effects [ Time Frame: Participants were followed for the duration of the study, approximately 44 weeks ]Side effects experienced by participants 1 to 2 days after Mepolizumab infusion.
- Number of Participants Who Experienced Specific Symptoms [ Time Frame: 44 weeks ]Number of participants who experienced specific symptoms during the trial.
- Steroid Dosing During Trial [ Time Frame: 20 weeks ]
- Evaluate Overall Positive Change in Churg-Strauss Syndrome Via the Measures Outlined in Study Aims [ Time Frame: 20 weeks ]The Asthma Control Questionnaire (ACQ) was one measure used to assess the prevalence of asthma symptoms the participant was having during the study. It is a series of 7 questions assessing how often, over the past two weeks, the participant wakes up from their asthma, how bad their symptoms were, etc. The greater the prevalence of symptoms, the higher the score. Each of the 7 questions is scored 0-6. The total score is calculated by adding the individual question scores and dividing the sum by 7.
- Efficacy- Exacerbation Rate [ Time Frame: Treatment period (12 weeks) ]Quantified the exacerbation rate (total number of exacerbations per day) of the participants during treatment with mepolizumab and without treatment. Exacerbations were characterized as any worsening of clinical disease requiring an increase of systemic corticosteroid therapy (e.g. prednisone) for asthma, respiratory symptoms, or underlying vasculitis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00527566
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Michael Wechsler, MD||Brigham and Women's Hospital|